From the Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, and Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (B.T.B.); Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts (S.H.-D.); Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (J.P.R.); and Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (J.D.S., M.D., M.A.F., K.F.H.).
Anesthesiology. 2014 May;120(5):1216-24. doi: 10.1097/ALN.0000000000000172.
There are few data regarding the utilization of opioids during pregnancy. The objective of this study was to define the prevalence and patterns of opioid use in a large cohort of pregnant women who were commercial insurance beneficiaries.
Data for the study were derived from a deidentified research database of women from across the United States who had both medical and prescription benefits. By using diagnostic codes, the authors defined a cohort of 534,500 women with completed pregnancies who were enrolled in a commercial insurance plan from 6 months before pregnancy through delivery.
Overall, 76,742 women (14.4%) were dispensed an opioid at some point during pregnancy. There were 30,566 women (5.7%) dispensed an opioid during the first trimester, 30,434 women (5.7%) during the second trimester, and 34,906 women (6.5%) during the third trimester. Of these, 11,747 women (2.2%) were dispensed opioids three or more times during pregnancy. The most commonly dispensed opioids during pregnancy were hydrocodone (6.8%), codeine (6.1%), and oxycodone (2.0%). The prevalence of exposure at anytime during pregnancy decreased slightly during the study period from 14.9% for pregnancies that delivered in 2005 to 12.9% in 2011. The prevalence of exposure varied significantly by region and was lowest in the Northeast and highest in the South.
This study demonstrates that opioids are very common exposures during pregnancy. Given the small and inconsistent body of literature on their safety in pregnancy, these findings suggest a need for research in this area.
关于孕妇使用阿片类药物的数据很少。本研究的目的是在一个大型商业保险受益孕妇队列中确定阿片类药物的使用频率和模式。
本研究的数据来自美国各地女性的一个匿名研究数据库,这些女性既有医疗福利又有处方福利。作者通过诊断代码定义了一个 534500 名完成妊娠的妇女队列,这些妇女在商业保险计划中从怀孕前 6 个月到分娩期间入组。
总体而言,76742 名妇女(14.4%)在怀孕期间的某个时间点开了阿片类药物。有 30566 名妇女(5.7%)在孕早期开了阿片类药物,30434 名妇女(5.7%)在孕中期开了阿片类药物,34906 名妇女(6.5%)在孕晚期开了阿片类药物。其中,11747 名妇女(2.2%)在怀孕期间开了三次或三次以上的阿片类药物。怀孕期间最常开的阿片类药物是氢可酮(6.8%)、可待因(6.1%)和羟考酮(2.0%)。在整个研究期间,怀孕期间任何时候暴露于阿片类药物的比例从 2005 年分娩的孕妇的 14.9%略有下降到 2011 年的 12.9%。暴露率因地区而异,东北部最低,南部最高。
本研究表明阿片类药物在怀孕期间非常常见。鉴于关于其在怀孕期间安全性的文献很少且不一致,这些发现表明需要在这一领域进行研究。